Tonix Pharmaceuticals Announces Publication Reporting a Potential Smallpox-Preventing Vaccine Candidate

Tonix Pharmaceuticals (Nasdaq:TNXP) a company developing innovative pharmaceutical and biological products to address major public health challenges, announced the publication of research describing the successful synthesis and characterization of a potential smallpox-preventing vaccine based on horsepox virus.
As quoted in the press release:

The peer-reviewed article, “Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments,” published in the journal PLOS ONE, follows the announcement in March of 2017 of the complete synthesis of horsepox virus using synthetic biology technology. The synthetic horsepox virus demonstrated the ability to protect against lethal vaccinia infection in a mouse model which may be indicative of vaccine protection in humans.

Click here to read the full press release.